Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis
Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events. Material and Methods: In this retrospective study, we analyzed a cohort of patients with metastatic soli...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2022-12-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | https://www.brazilianjournalofoncology.com.br/details/231/en-US/patterns-of-immune-related-adverse-events-in-patients-treated-with-immune-checkpoint-inhibitors--a-brazilian-real-world-analysis |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849702431031558144 |
|---|---|
| author | Maria Paula Furtado Santos Allan Andersson Lima Pereira Luiza Nardin Weis Ana Carolina de Aquino Diniz Rodrigo Bovolin de Medeiros Artur Katz Igor Alexandre Protzner Morbeck Gustavo dos Santos Fernandes Rodrigo Ramela Munhoz Romualdo Barroso-Sousa |
| author_facet | Maria Paula Furtado Santos Allan Andersson Lima Pereira Luiza Nardin Weis Ana Carolina de Aquino Diniz Rodrigo Bovolin de Medeiros Artur Katz Igor Alexandre Protzner Morbeck Gustavo dos Santos Fernandes Rodrigo Ramela Munhoz Romualdo Barroso-Sousa |
| author_sort | Maria Paula Furtado Santos |
| collection | DOAJ |
| description | Objectives:
To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events.
Material and Methods:
In this retrospective study, we analyzed a cohort of patients with metastatic solid tumors treated at an oncology reference center with at least one dose of immune-checkpoint inhibitors (given as monotherapy or in combination with other agents). The safety profile was characterized through the incidence of adverse events, management and hospitalization.
Results:
We included 185 patients. Immune-related adverse events were observed in 92 of the 185 study patients (49.7%), including 16 patients (8.6%) with such events of grade 3 or 4, and 28 patients (15.1%) requiring systemic corticosteroid therapy. Thyroid disorders (20%), rash (17.8%), pruritus (11.4%) and colitis (11.4%) were the most frequent immune-related adverse events. Five (2.7%) patients discontinued immune-checkpoint inhibitors and 15 (7.0%) were hospitalized due to immune-related adverse events. Development of immune-related adverse events and immune-checkpoint inhibitors used in the firstline setting were associated with prolonged progression-free survival and overall survival in the multivariate analysis. Moreover, age <75 years old and ECOG score 0 or 1 were positively associated with overall survival in the multivariate analysis.
Conclusion:
This study based upon a Brazilian “real-world” data confirms the toxicity profile of immune-checkpoint inhibitors seen in clinical trials. In accordance with previous retrospective analyses, development of immune-related adverse events was associated with survival outcome of immune-checkpoint inhibitors treatment in patients with metastatic solid cancers. |
| format | Article |
| id | doaj-art-1dcef85cf2eb4b6b9bbef35b89c5d451 |
| institution | DOAJ |
| issn | 2526-8732 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Thieme Revinter Publicações Ltda. |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj-art-1dcef85cf2eb4b6b9bbef35b89c5d4512025-08-20T03:17:39ZengThieme Revinter Publicações Ltda.Brazilian Journal of Oncology2526-87322022-12-01180010.5935/2526-8732.20220367Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysisMaria Paula Furtado Santos0Allan Andersson Lima Pereira1Luiza Nardin Weis2Ana Carolina de Aquino Diniz3Rodrigo Bovolin de Medeiros4Artur Katz5Igor Alexandre Protzner Morbeck6Gustavo dos Santos Fernandes7Rodrigo Ramela Munhoz8Romualdo Barroso-Sousa9Hospital Sírio-Libanês, Institute of teaching and research - Brasília - DF - BrazilHospital Sírio-Libanês, Oncology Center - Brasília - DF - BrazilHospital Sírio-Libanês, Institute of teaching and research - Brasília - DF - BrazilHospital Sírio-Libanês, Institute of teaching and research - Brasília - DF - BrazilHospital Sírio-Libanês, Oncology Center - Brasília - DF - BrazilHospital Sírio-Libanês, Oncology Center - São Paulo - SP - BrazilHospital Sírio-Libanês, Oncology Center - Brasília - DF - BrazilHospital Sírio-Libanês, Oncology Center - São Paulo - SP - BrazilHospital Sírio-Libanês, Oncology Center - São Paulo - SP - BrazilHospital Sírio-Libanês, Oncology Center - São Paulo - SP - BrazilObjectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events. Material and Methods: In this retrospective study, we analyzed a cohort of patients with metastatic solid tumors treated at an oncology reference center with at least one dose of immune-checkpoint inhibitors (given as monotherapy or in combination with other agents). The safety profile was characterized through the incidence of adverse events, management and hospitalization. Results: We included 185 patients. Immune-related adverse events were observed in 92 of the 185 study patients (49.7%), including 16 patients (8.6%) with such events of grade 3 or 4, and 28 patients (15.1%) requiring systemic corticosteroid therapy. Thyroid disorders (20%), rash (17.8%), pruritus (11.4%) and colitis (11.4%) were the most frequent immune-related adverse events. Five (2.7%) patients discontinued immune-checkpoint inhibitors and 15 (7.0%) were hospitalized due to immune-related adverse events. Development of immune-related adverse events and immune-checkpoint inhibitors used in the firstline setting were associated with prolonged progression-free survival and overall survival in the multivariate analysis. Moreover, age <75 years old and ECOG score 0 or 1 were positively associated with overall survival in the multivariate analysis. Conclusion: This study based upon a Brazilian “real-world” data confirms the toxicity profile of immune-checkpoint inhibitors seen in clinical trials. In accordance with previous retrospective analyses, development of immune-related adverse events was associated with survival outcome of immune-checkpoint inhibitors treatment in patients with metastatic solid cancers.https://www.brazilianjournalofoncology.com.br/details/231/en-US/patterns-of-immune-related-adverse-events-in-patients-treated-with-immune-checkpoint-inhibitors--a-brazilian-real-world-analysisbrazilimmunotherapyimmune checkpoint inhibitorstoxicity |
| spellingShingle | Maria Paula Furtado Santos Allan Andersson Lima Pereira Luiza Nardin Weis Ana Carolina de Aquino Diniz Rodrigo Bovolin de Medeiros Artur Katz Igor Alexandre Protzner Morbeck Gustavo dos Santos Fernandes Rodrigo Ramela Munhoz Romualdo Barroso-Sousa Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis Brazilian Journal of Oncology brazil immunotherapy immune checkpoint inhibitors toxicity |
| title | Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis |
| title_full | Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis |
| title_fullStr | Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis |
| title_full_unstemmed | Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis |
| title_short | Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis |
| title_sort | patterns of immune related adverse events in patients treated with immune checkpoint inhibitors a brazilian real world analysis |
| topic | brazil immunotherapy immune checkpoint inhibitors toxicity |
| url | https://www.brazilianjournalofoncology.com.br/details/231/en-US/patterns-of-immune-related-adverse-events-in-patients-treated-with-immune-checkpoint-inhibitors--a-brazilian-real-world-analysis |
| work_keys_str_mv | AT mariapaulafurtadosantos patternsofimmunerelatedadverseeventsinpatientstreatedwithimmunecheckpointinhibitorsabrazilianrealworldanalysis AT allananderssonlimapereira patternsofimmunerelatedadverseeventsinpatientstreatedwithimmunecheckpointinhibitorsabrazilianrealworldanalysis AT luizanardinweis patternsofimmunerelatedadverseeventsinpatientstreatedwithimmunecheckpointinhibitorsabrazilianrealworldanalysis AT anacarolinadeaquinodiniz patternsofimmunerelatedadverseeventsinpatientstreatedwithimmunecheckpointinhibitorsabrazilianrealworldanalysis AT rodrigobovolindemedeiros patternsofimmunerelatedadverseeventsinpatientstreatedwithimmunecheckpointinhibitorsabrazilianrealworldanalysis AT arturkatz patternsofimmunerelatedadverseeventsinpatientstreatedwithimmunecheckpointinhibitorsabrazilianrealworldanalysis AT igoralexandreprotznermorbeck patternsofimmunerelatedadverseeventsinpatientstreatedwithimmunecheckpointinhibitorsabrazilianrealworldanalysis AT gustavodossantosfernandes patternsofimmunerelatedadverseeventsinpatientstreatedwithimmunecheckpointinhibitorsabrazilianrealworldanalysis AT rodrigoramelamunhoz patternsofimmunerelatedadverseeventsinpatientstreatedwithimmunecheckpointinhibitorsabrazilianrealworldanalysis AT romualdobarrososousa patternsofimmunerelatedadverseeventsinpatientstreatedwithimmunecheckpointinhibitorsabrazilianrealworldanalysis |